Disc Medicine (IRON) Free Cash Flow (2020 - 2026)
Disc Medicine (IRON) reported Free Cash Flow of -$62.2 million for Q1 2026, down 47.38% year-over-year from -$118.3 million in Q1 2025, and down 43.67% on a QoQ basis from -$43.3 million in Q4 2025.
Disc Medicine (IRON) has 7 years of Free Cash Flow data on file, last reported at -$62.2 million in Q1 2026.
- Quarterly Free Cash Flow fell 47.38% year-over-year to -$62.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$201.3 million (down 95.49% YoY) and the FY2025 annual result came in at -$181.3 million, down 92.02% from the prior year.
- Free Cash Flow fell to -$62.2 million in Q1 2026 per IRON's latest filing, from -$43.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$7.5 million in Q3 2023 and bottomed at -$62.2 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$17.8 million (2023), against an average of -$26.7 million.
- The widest annual swing landed in 2022, when Free Cash Flow jumped 42.15%; it then slumped 211.59% in 2025.
- Tracing IRON's Free Cash Flow over 5 years: stood at -$9.7 million in 2022, then tumbled by 83.93% to -$17.8 million in 2023, then tumbled by 57.44% to -$28.0 million in 2024, then tumbled by 54.59% to -$43.3 million in 2025, then plunged by 43.67% to -$62.2 million in 2026.
- Per Business Quant, the three latest IRON Free Cash Flow figures stand at -$62.2 million (Q1 2026), -$43.3 million (Q4 2025), and -$47.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | -62.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.24 Mn |
| Mar 31, 2026 | -62.24 Mn |
| Dec 31, 2025 | -43.32 Mn |
| Dec 31, 2025 | -43.32 Mn |
| Sep 30, 2025 | -47.83 Mn |
| Sep 30, 2025 | -47.83 Mn |
| Jun 30, 2025 | -47.95 Mn |
| Jun 30, 2025 | -47.95 Mn |
| Mar 31, 2025 | -42.23 Mn |
| Mar 31, 2025 | -42.23 Mn |
| Dec 31, 2024 | -28.02 Mn |
| Dec 31, 2024 | -28.02 Mn |
| Sep 30, 2024 | -17.35 Mn |
| Sep 30, 2024 | -17.35 Mn |
| Jun 30, 2024 | -15.39 Mn |
| Jun 30, 2024 | -15.39 Mn |
| Mar 31, 2024 | -33.67 Mn |
| Mar 31, 2024 | -33.67 Mn |
| Dec 31, 2023 | -17.80 Mn |
| Dec 31, 2023 | -17.80 Mn |
| Sep 30, 2023 | -7.52 Mn |
| Sep 30, 2023 | -7.52 Mn |
| Jun 30, 2023 | -12.74 Mn |
| Jun 30, 2023 | -12.74 Mn |
| Mar 31, 2023 | -35.50 Mn |
| Mar 31, 2023 | -35.50 Mn |
| Dec 31, 2022 | -9.68 Mn |
| Dec 31, 2022 | -9.68 Mn |
| Sep 30, 2022 | -9.71 Mn |
| Sep 30, 2022 | -9.71 Mn |
| Jun 30, 2022 | -9.21 Mn |
| Jun 30, 2022 | -9.21 Mn |
| Mar 31, 2022 | -13.80 Mn |
| Mar 31, 2022 | -13.80 Mn |
| Dec 31, 2021 | 19.55 Mn |
| Dec 31, 2021 | 19.55 Mn |
| Sep 30, 2021 | -16.10 Mn |
| Sep 30, 2021 | -16.10 Mn |
| Jun 30, 2021 | -15.93 Mn |
| Jun 30, 2021 | -15.93 Mn |
| Mar 31, 2021 | -15.01 Mn |
| Mar 31, 2021 | -15.01 Mn |
| Dec 31, 2020 | -416,411.00 |
| Dec 31, 2020 | -416,411.00 |
| Sep 30, 2020 | -190,568.00 |
| Sep 30, 2020 | -190,568.00 |
| Jun 30, 2020 | -7.03 Mn |
| Jun 30, 2020 | -7.03 Mn |
| Mar 31, 2020 | -9.88 Mn |
| Mar 31, 2020 | -9.88 Mn |